Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2776 The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours

Introduction: Long acting somatostatin analogues (SSA) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Patel K

Authors: Patel K, Nahar A, Elhassan Y, Shah T, Ayuk J,

Keywords: Somatostatin analogues, Diabetes, Neuroendocrine tumour, HbA1c, BMI,

#2219 24 Hour Urinary 5-Hydroxyindoleacetic Acid Levels in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors

Introduction: The secretion of urinary 5-Hydroxyindoleacetic Acid (u5-HIAA) by non-functioning PNETs (NF-PNET) has rarely been reported, and the data on the association between u5-HIAA levels and disease burden is scant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Tirosh A

Authors: Tirosh A, Papadakis G, Sadowsi S, Patel D, Nilubol N,

Keywords: 5-HIAA, PNET, Secretion, Biomarker,

#1853 24 Hour Urinary 5-Hydroxyindoleacetic Acid (5HIAA) and Vasoactive Intestinal Peptide (VIP) Doubling-Times (DTs) Predict Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)

Introduction: New clinical prognostic tools are needed in order to select patients with NETs that are at higher risk of DSM. Biochemical biomarker DT is used clinically for prognosis prediction in several solid malignancies

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Tirosh A

Authors: Tirosh A, Nilubol N, Patel D, Kebebew E,

Keywords: doubling time, biomarker, prognosis,

#1825 The Effect of PRRT on Health-Related Quality of Life in NET Patients: A Prospective Study

Introduction: Neuroendocrine tumour (NET) patients experience poor health-related quality of life (HRQOL). Peptide receptor radionuclide therapy (PRRT) is a promising treatment option although its impact on HRQOL is not well understood.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Patel D, Corsini N, Lawrie J, Nicholls D, Imogen R,

Keywords: PRRT, quality of life , Lutate,

#1006 The Use of Endoluminal Stents to Overcome Vascular Obstruction Arising from Mesenteric and Retroperitoneal Neuroendocrine Metastases

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) often metastasise to lymph nodes. Nodal metastases from neuroendocrine tumors in the distal small intestine commonly (>50%) develop in the mesentery and are often centred at the mesenteric root surrounding the major vessels supplying the bowel. Compression of these vessels, by the nodes or associated fibrosis, can lead to severe symptoms such as pain (secondary to bowel ischaemia ), ascites (from superior mesenteric vein obstruction) and bowel perforation. In view of the often indolent nature of GEP-NET, symptoms from lymph node masses can persist for years, causing significant morbidity and early mortality.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Anthoney A, Patel J, Kamposioras K,

Keywords: gastroenteropancreatic neuroendocrine tumor, endoluminal stent, mesentery,